The Rheumatology Research Workshop is a two- day workshop designed to promote interactions between young and established investigators to foster collaboration and career mentoring. The 2012 Research Workshop will be held at the Omni Interlocken Resort in Denver Colorado from May 4-6.
The meeting will include scientific lectures, oral abstract presentations, poster sessions and scheduled time for interaction with senior investigators to exchange ideas with trainees and other early career investigators.
REGISTRATION IS NOW CLOSED
Please check back in the fall for details on the 2013 Workshop
TRAVEL AWARD CRITERIA
- Abstract submissions from the 2011 ACR/ARHP Annual Scientific Meeting are allowed.
- Abstract submission and acceptance is required for all meeting attendees.
- Abstracts submitted will be used as the basis for awarding the scholarship. Scholarship recipients will be selected based on the quality of science of the abstract.
- Only one abstract submission allowed per applicant.
- Applicants must be an ACR member at time of application (membership is not a requirement for medical students or residents).
AND an applicant can either be:
- A medical student or resident enrolled in an ACGME-accredited pediatric, medicine or combined medicine/pediatric residency program who is interested in rheumatology
- A fellow-in-training at an ACGME-accredited training program, that will lead to eligibility to take the ABIM examination in rheumatology or the ABP examination in pediatric rheumatology
- A faculty member within six years of completing their fellowship training program
- Have a doctoral level degree, including but not limited to MD, DO, or MD/PhD.
Travel Awards are available on a first-come, first-served basis and include:
- 2-nights hotel room and tax charges only
- Roundtrip economy/coach airfare to Denver, Colorado from the participant's home city
- A stipend to cover ground transportation to and from the airport
Funding for this program was made possible in part by support from the American College of Rheumatology Fellows Educational Fund and the Arthritis Foundation.
The abstract limit is 2,750 characters, which includes the title, authors and affiliations, excluding spacing or disclosures. In addition, if you import tables and graphics, your character count will decrease by 250 characters from the total limit allowed. Your abstract will be considered “incomplete” if you exceed the limit.
Title
Titles should be brief, clearly indicating the nature of the presentation. When entering your title online, use mixed case (do not use all caps), and do not put a period at the end of the title. Do not enter the title in the body of the abstract.
Example: This is a Properly Formatted Abstract Title
Authors
You may list no more than 25 individual authors for each abstract. In addition to the 25 authors, an authoring group may be listed to indicate the remaining authors.
Content
Omit all names and geographical references in the body of the abstract. Organize content as follows:
- Background or Statement of Purpose
- Methods, materials and analytical procedure used
- Summary of the results in sufficient detail to support conclusion
- Conclusions reached (do not state "results will be discussed")
Use of Product Names
The non-proprietary (generic/scientific) name can be used in your abstract. The proprietary drug name may appear once in parentheses in the title only. However, if a drug has not received FDA approval, only the non-proprietary name may be used in the title and abstract. Failure to follow this rule will result in disqualification of your submission.
Abbreviations
Use standard abbreviations. Place special or unusual abbreviations in parentheses after the first time the full word appears. Do not abbreviate compounds in the title of the abstract. Use numerals to indicate numbers, except when beginning sentences.
Tables and Graphics
Specific information regarding acceptable graphic files is included in the Online Submission Program. Microsoft PowerPoint® files are not accepted.
All abstracts must be submitted online at the time of registration by the registration deadline, February 6, 2012.
Before starting the online application, please read these instructions.
- All files must be in MS Word format and saved as ".doc" files
- Use one inch margins, Arial font and 11-point font size (does not apply to figures and tables)
- The header of each page must contain the applicant’s last name and first initial (formatted as last name, first initial)
- Filenames should be named applicants last name (e.g., "Smith") and must not exceed 15 characters in length
Abstract Eligibility
- Abstracts describing original basic and clinical work related to the broad area of rheumatic diseases may be submitted.
- An abstract is ineligible for consideration if it reports work that has been accepted for publication as a manuscript prior to the ACR submission deadline of February 6, 2012.
- The same study should not be submitted as multiple abstracts. Abstracts that appear as more than one version of a single study will be rejected.
- By submitting your abstract, you agree to present the abstract if it is selected for presentation during an oral or poster abstract presentation.
- Case reports submitted to the ACR program are not considered appropriate and will not be reviewed.
- If the abstract reports results of a clinical trial not yet approved by a regulatory agency, the presenting author will be required to identify the trial phase.
- Any work with human or animal subjects reported in submitted abstracts must comply with the guiding principles for experimental procedures found in the Declaration of Helsinki of the World Medical Association.
After the submission deadline, all complete abstracts in the system will be sent for review. Any abstracts left “incomplete” will not reviewed.
- Accepted abstracts will be programmed as either a short oral presentation or a poster presentation. The Review Committee will determine the format based on the abstract topic and the relationship to others in the review categories.
- The Presenting Author will be notified in early March. The Presenting Author is the only author who will receive notification and is the point of contact for all other authors on the abstract.
- All abstracts will be reviewed without knowledge of the author(s), institution(s) or disclosure information.
